



Vienna (CET)	Day 1 January 28	Day 2 January 29	Day 3 January 30	Day 4 January 31
		<b>Antibody</b> <b>Health Services</b> <b>Immunotherapy</b> <b>Diagnostic/Pulmonology and Targeted Therapies</b> <b>Locoregional/Oligo</b> <b>Early Stage</b>	<b>Immuno-Biology</b> <b>Pathology</b> <b>Screening/ED</b> <b>Mesothelioma</b> <b>Nursing/AHP</b> <b>Patient Advocacy</b>	<b>Palliative Care</b> <b>Targeted Therapies</b> <b>Risk Reduction and Tobacco Control</b> <b>SCLC/NET</b> <b>Staging</b> <b>Tumor Biology</b>
24:00 - 02:00	Joint IASLC-CAALC-CSCO Session*	<b>PL02: Innovation to Bridge Lung Cancer Care Tomorrow</b> ★ Live Q&A		
02:15 - 03:15	<b>IS01: Satellite CME Symposium by Clinical Care Options**</b> ★	<b>ES01: Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC</b> ★ <b>OA01: Established Drugs in Special Populations and New Drugs in Established Populations</b> ★ <b>OA02: Updates in Locally Advanced NSCLC</b> ★ Live Q&A	<b>ES09: Biomarkers in Immunotherapy</b> ★ <b>ES10: Advances in Lung Cancer Screening Through Imaging and Data Analytics</b> ★ <b>ES11: Practice-Changing Initiatives</b> ★ Live Q&A	<b>ES20: Evidence Base for Symptom Management</b> ★ <b>ES21: The "How To" of Modern Tobacco Control</b> ★ <b>MA09: Prognosis and Staging</b> ★ Live Q&A
03:30 - 04:30	<b>IS02: Industry Symposium*</b>	<b>OA03: Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC</b> ★ <b>ES02: Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?</b> ★ <b>ES03: Understanding and Treating Oligometastatic Diseases</b> ★ Live Q&A	<b>OA07: Immuno-biology and Novel Immunotherapeutics from Bench to Bed</b> ★ <b>ES12: Public Health Issues in Lung Cancer Screening</b> ★ Live Q&A	<b>ES22: Quality of Life</b> ★ <b>OA10: The Slow Pandemic - Tobacco Control in the Prevention of Lung Cancer</b> ★ <b>ES23: Beyond the TNM</b> ★ Live Q&A
04:45 - 05:45	<b>IS03: Industry Symposium*</b>	<b>MA01: Novel Systemic Treatment in NSCLC</b> ★ <b>OA04: New Data from Rare EGFR Alterations</b> ★ <b>ES04: Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond</b> ★ Live Q&A	<b>ES14: Novel Immunotherapy Strategies in NSCLC</b> ★ <b>MA05: Lung Cancer Screening</b> ★ <b>OA08: Putting the Patient at the Center: Holistic Patient Care</b> ★ Live Q&A	<b>MA10: Assessing and Managing Supportive Care Needs</b> ★ <b>ES24: Challenges in Tobacco Control</b> ★ <b>ES25: Unmet Need Issues of Current TNM</b> ★ Live Q&A
06:00 - 07:00	<b>IS04: Industry Symposium*</b>	<b>IS08: Industry Symposium*</b> <b>IS09: Industry Symposium*</b> <b>IS10: Industry Symposium*</b>	<b>IS11: Industry Symposium*</b> <b>IS12: Industry Symposium*</b> <b>IS13: Satellite CME Symposium by ACE Oncology**</b> ★	<b>IS14: Industry Symposium*</b> <b>IS15: Industry Symposium*</b>
07:15 - 08:15	<b>IS05: Industry Symposium*</b>	<b>ES05: Value in Lung Cancer, from Screening to Treatment</b> ★ <b>MA02: Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer</b> ★ <b>ES06: Perioperative Therapy for Early Stage NSCLC</b> ★ Live Q&A	<b>ES15: Getting All NSCLCs Genotyped: How Can We Get to 100%?</b> ★ <b>MA06: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma</b> ★ <b>ES16: Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates</b> ★ Live Q&A	<b>MA11: Expanding Targetable Genetic Alterations in NSCLC</b> ★ <b>ES26: Future Horizons in the Management of Small Cell Lung Cancer</b> ★ <b>ES27: Heterogeneity, Metastases and Resistance</b> ★ Live Q&A
08:30 - 09:30	<b>IS06: Industry Symposium*</b>	<b>OA05: Value and Quality in Lung Cancer</b> ★ <b>ES07: Pleural Effusion in a Cancer Patient</b> ★ <b>MA03: New and Revisited Factors in Early Stage Lung Cancer</b> ★ Live Q&A	<b>ES17: The New WHO Classification of Lung Tumors</b> ★ <b>OA09: Mesothelioma from Pathogenesis to Therapy</b> ★ <b>MA07: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19</b> ★ Live Q&A	<b>ES28: Targeting KRAS</b> ★ <b>OA11: A Symphony of Progress</b> ★ <b>ES29: Advances in Omics - Next Generation</b> ★ Live Q&A
09:45 - 10:45	<b>IS07: Industry Symposium*</b>	<b>MA04: Health Policy and the Real World</b> ★ <b>ES08: The Solitary Pulmonary Nodule</b> ★ <b>OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy</b> ★ Live Q&A	<b>MA08: Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non-Small Cell Lung Carcinoma</b> ★ <b>ES18: The Future of Immunotherapy in Unresectable Mesothelioma</b> ★ <b>ES19: Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients</b> ★ Live Q&A	<b>ES30: What is the Best Treatment Strategy to Target Rare Mutations</b> ★ <b>MA12: Controversies Old and New</b> ★ <b>MA13: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment</b> ★ Live Q&A
11:00 - 13:00	<b>PL01: Opening Plenary Session</b> ★ Live Q&A	<b>PL03: Bench to Bedside (Immunology)</b> ★ Live Q&A	<b>PS02: Presidential Symposium (Rebroadcasted)</b> ★ Live Q&A	<b>PL05: Affordable and Accessible Lung Cancer Care</b> ★ Live Q&A

**PL - Plenary**   
**PS - Presidential Symposium**   
**ES - Education Session**   
**OA - Oral Session**   
**MA - Mini Oral Session**   
**IS - Industry Symposium or Satellite CME Symposium**   
★ **IASLC CME Accredited**   
★ **CME Accredited by Other Provider**

\*Not for CME Credit, see page 2 for more details for more information about the Industry Symposium sessions.

\*\*CME Accredited by Other Provider, see page 2 for more details.

Vienna (CET)	Day 1 January 28	Day 2 January 29			Day 3 January 30	Day 4 January 31	
24:00 - 02:00							
02:15 - 03:15	<b>IS01:</b> Satellite CME Symposium by Clinical Care Options: Advances in Antibody-Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer						
03:30 - 04:30	<b>IS02:</b> Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC						
04:45 - 05:45	<b>IS03:</b> Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges						
06:00 - 07:00	<b>IS04:</b> Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices	<b>IS08:</b> Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs	<b>IS09:</b> Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC	<b>IS10:</b> Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO	<b>IS11:</b> Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies	<b>IS12:</b> Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC	<b>IS13:</b> Satellite CME Symposiumby ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
07:15 - 08:15	<b>IS05:</b> Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer						
08:30 - 09:30	<b>IS06:</b> Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC						
09:45 - 10:45	<b>IS07:</b> Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer						
11:00 - 13:00							